BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39:540-543. [PMID: 15942443 DOI: 10.1097/01.mcg.0000165671.25272.0f] [Cited by in Crossref: 297] [Cited by in F6Publishing: 277] [Article Influence: 18.6] [Reference Citation Analysis]
Number Citing Articles
1 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Reference Citation Analysis]
2 Kanmani P, Ansari A, Villena J, Kim H. Immunobiotics Beneficially Modulate TLR4 Signaling Triggered by Lipopolysaccharide and Reduce Hepatic Steatosis In Vitro. J Immunol Res 2019;2019:3876896. [PMID: 31001563 DOI: 10.1155/2019/3876896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Manco M, Putignani L, Bottazzo GF. Gut Microbiota, Lipopolysaccharides, and Innate Immunity in the Pathogenesis of Obesity and Cardiovascular Risk. Endocrine Reviews 2010;31:817-44. [DOI: 10.1210/er.2009-0030] [Cited by in Crossref: 268] [Cited by in F6Publishing: 247] [Article Influence: 24.4] [Reference Citation Analysis]
4 Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009;51:212-223. [PMID: 19447517 DOI: 10.1016/j.jhep.2009.03.008] [Cited by in Crossref: 300] [Cited by in F6Publishing: 287] [Article Influence: 25.0] [Reference Citation Analysis]
5 Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J, Liu H. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol 2020;55:142-58. [PMID: 31845054 DOI: 10.1007/s00535-019-01649-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
6 Petrella C, Strimpakos G, Torcinaro A, Middei S, Ricci V, Gargari G, Mora D, De Santa F, Farioli-Vecchioli S. Proneurogenic and neuroprotective effect of a multi strain probiotic mixture in a mouse model of acute inflammation: Involvement of the gut-brain axis. Pharmacol Res 2021;172:105795. [PMID: 34339837 DOI: 10.1016/j.phrs.2021.105795] [Reference Citation Analysis]
7 Sheth AA, Garcia-Tsao G. Probiotics and liver disease. J Clin Gastroenterol. 2008;42 Suppl 2:S80-S84. [PMID: 18542037 DOI: 10.1097/mcg.0b013e318169c44e] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
8 Anderson N, Borlak J. Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacol Rev 2008;60:311-57. [DOI: 10.1124/pr.108.00001] [Cited by in Crossref: 260] [Cited by in F6Publishing: 234] [Article Influence: 20.0] [Reference Citation Analysis]
9 Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci 2016;17:E947. [PMID: 27314342 DOI: 10.3390/ijms17060947] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 15.4] [Reference Citation Analysis]
10 Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol. 2015;7:425-442. [PMID: 25848468 DOI: 10.4254/wjh.v7.i3.425] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 15.7] [Reference Citation Analysis]
11 Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2010;9:42. [PMID: 20426802 DOI: 10.1186/1476-511x-9-42] [Cited by in Crossref: 108] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
12 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716. [PMID: 28230908 DOI: 10.1002/14651858.cd008716.pub3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
13 Kwak DS, Jun DW, Seo JG, Chung WS, Park SE, Lee KN, Khalid-Saeed W, Lee HL, Lee OY, Yoon BC, Choi HS. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. Eur J Gastroenterol Hepatol 2014;26:1353-9. [PMID: 25244414 DOI: 10.1097/MEG.0000000000000214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
14 Jin P, Chen Y, Lv L, Yang J, Lu H, Li L. Lactobacillus fermentum ZYL0401 Attenuates Lipopolysaccharide-Induced Hepatic TNF-α Expression and Liver Injury via an IL-10- and PGE2-EP4-Dependent Mechanism. PLoS One 2015;10:e0126520. [PMID: 25978374 DOI: 10.1371/journal.pone.0126520] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
15 Hernandez-Rodas MC, Valenzuela R, Videla LA. Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2015;16:25168-98. [PMID: 26512643 DOI: 10.3390/ijms161025168] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 11.5] [Reference Citation Analysis]
16 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
17 Usami M, Miyoshi M, Kanbara Y, Aoyama M, Sakaki H, Shuno K, Hirata K, Takahashi M, Ueno K, Tabata S. Effects of perioperative synbiotic treatment on infectious complications, intestinal integrity, and fecal flora and organic acids in hepatic surgery with or without cirrhosis. JPEN J Parenter Enteral Nutr. 2011;35:317-328. [PMID: 21527594 DOI: 10.1177/0148607110379813] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
18 Preveden T, Scarpellini E, Milić N, Luzza F, Abenavoli L. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2017;11:813-9. [PMID: 28621554 DOI: 10.1080/17474124.2017.1343663] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 10.5] [Reference Citation Analysis]
19 Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol 2018;15:467-79. [PMID: 29413959 DOI: 10.1016/j.redox.2018.01.009] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 27.0] [Reference Citation Analysis]
20 Taneja SK, Dhiman RK. Prevention and management of bacterial infections in cirrhosis. Int J Hepatol 2011;2011:784540. [PMID: 22229097 DOI: 10.4061/2011/784540] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
21 Turroni F, Ventura M, Buttó LF, Duranti S, O'Toole PW, Motherway MO, van Sinderen D. Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective. Cell Mol Life Sci 2014;71:183-203. [PMID: 23516017 DOI: 10.1007/s00018-013-1318-0] [Cited by in Crossref: 163] [Cited by in F6Publishing: 136] [Article Influence: 20.4] [Reference Citation Analysis]
22 Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: REVIEW: CURRENT MANAGEMENT OF NAFLD AND NASH. Alimentary Pharmacology & Therapeutics 2008;28:2-12. [DOI: 10.1111/j.1365-2036.2008.03710.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 90] [Article Influence: 7.8] [Reference Citation Analysis]
23 Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120-127. [PMID: 23401313 DOI: 10.1002/hep.26319] [Cited by in Crossref: 401] [Cited by in F6Publishing: 353] [Article Influence: 50.1] [Reference Citation Analysis]
24 Scarpellini E, Fagoonee S, Rinninella E, Rasetti C, Aquila I, Larussa T, Ricci P, Luzza F, Abenavoli L. Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. J Clin Med 2020;9:E2488. [PMID: 32756323 DOI: 10.3390/jcm9082488] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
25 Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients. 2011;3:637-682. [PMID: 22254115 DOI: 10.3390/nu3060637] [Cited by in Crossref: 217] [Cited by in F6Publishing: 185] [Article Influence: 21.7] [Reference Citation Analysis]
26 Gu Z, Wu Y, Wang Y, Sun H, You Y, Piao C, Liu J. Lactobacillus rhamnosus Granules Dose-Dependently Balance Intestinal Microbiome Disorders and Ameliorate Chronic Alcohol-Induced Liver Injury.J Med Food. 2020;23:114-124. [PMID: 31747353 DOI: 10.1089/jmf.2018.4357] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
27 Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014;18:59-71. [PMID: 24274865 DOI: 10.1016/j.cld.2013.09.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
28 Bhathena J, Martoni C, Kulamarva A, Tomaro-Duchesneau C, Malhotra M, Paul A, Urbanska AM, Prakash S. Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in Bio F1B Golden Syrian hamsters. PLoS One. 2013;8:e58394. [PMID: 23554890 DOI: 10.1371/journal.pone.0058394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
29 Cinque B, La Torre C, Lombardi F, Palumbo P, Van der Rest M, Cifone MG. Production Conditions Affect the In Vitro Anti-Tumoral Effects of a High Concentration Multi-Strain Probiotic Preparation. PLoS One 2016;11:e0163216. [PMID: 27657913 DOI: 10.1371/journal.pone.0163216] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
30 Satish Kumar CS, Kondal Reddy K, Boobalan G, Gopala Reddy A, Sudha Rani Chowdhary CH, Vinoth A, Jayakanth K, Srinivasa Rao G. Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. Res Vet Sci. 2017;110:40-46. [PMID: 28159236 DOI: 10.1016/j.rvsc.2016.10.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
31 Federico A, Niosi M, Vecchio Blanco CD, Loguercio C. Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008;13:145-158. [PMID: 18321154 DOI: 10.1517/14728214.13.1.145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
32 Tan H, Chang JP. Non-Alcoholic Fatty Liver Disease. Proceedings of Singapore Healthcare 2010;19:36-50. [DOI: 10.1177/201010581001900106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
33 Chen Y, Li R, Chang Q, Dong Z, Yang H, Xu C. Lactobacillus bulgaricus or Lactobacillus rhamnosus Suppresses NF-κB Signaling Pathway and Protects against AFB₁-Induced Hepatitis: A Novel Potential Preventive Strategy for Aflatoxicosis? Toxins (Basel) 2019;11:E17. [PMID: 30621122 DOI: 10.3390/toxins11010017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
34 Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69:211-20. [DOI: 10.1017/s0029665110000030] [Cited by in Crossref: 141] [Cited by in F6Publishing: 64] [Article Influence: 12.8] [Reference Citation Analysis]
35 Hartmann P, Chen WC, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol 2012;3:402. [PMID: 23087650 DOI: 10.3389/fphys.2012.00402] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
36 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease 2009;41:615-25. [DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 174] [Cited by in F6Publishing: 163] [Article Influence: 14.5] [Reference Citation Analysis]
37 Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4:325-339. [PMID: 23842110 DOI: 10.4161/gmic.25487] [Cited by in Crossref: 183] [Cited by in F6Publishing: 148] [Article Influence: 22.9] [Reference Citation Analysis]
38 Heineman J, Bubenik S, McClave S, Martindale R. Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases? Curr Gastroenterol Rep. 2012;14:343-348. [PMID: 22763792 DOI: 10.1007/s11894-012-0274-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
39 D’mello C, Swain MG. Immune-to-Brain Communication Pathways in Inflammation-Associated Sickness and Depression. In: Dantzer R, Capuron L, editors. Inflammation-Associated Depression: Evidence, Mechanisms and Implications. Cham: Springer International Publishing; 2017. pp. 73-94. [DOI: 10.1007/7854_2016_37] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 15.0] [Reference Citation Analysis]
40 Rashid SK, Idris-Khodja N, Auger C, Alhosin M, Boehm N, Oswald-Mammosser M, Schini-Kerth VB. Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system. PLoS One. 2014;9:e97458. [PMID: 24832090 DOI: 10.1371/journal.pone.0097458] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
41 Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 9.2] [Reference Citation Analysis]
42 Tao X, Wang N, Qin W. Gut Microbiota and Hepatocellular Carcinoma. Gastrointest Tumors. 2015;2:33-40. [PMID: 26673641 DOI: 10.1159/000380895] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
43 Chiu YH, Lu YC, Ou CC, Lin SL, Tsai CC, Huang CT, Lin MY. Lactobacillus plantarum MYL26 induces endotoxin tolerance phenotype in Caco-2 cells. BMC Microbiol. 2013;13:190. [PMID: 23937116 DOI: 10.1186/1471-2180-13-190] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
44 Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J Pediatr Gastroenterol Nutr 2017;64:413-7. [PMID: 28230607 DOI: 10.1097/MPG.0000000000001422] [Cited by in Crossref: 89] [Cited by in F6Publishing: 42] [Article Influence: 29.7] [Reference Citation Analysis]
45 Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117:662-668. [PMID: 28345499 DOI: 10.1017/s0007114517000204] [Cited by in Crossref: 87] [Cited by in F6Publishing: 39] [Article Influence: 21.8] [Reference Citation Analysis]
46 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
47 Toffanin S, Cornella H, Harrington A, Llovet JM. HCC Is promoted by bacterial translocation and TLR-4 signaling: a new paradigm for chemoprevention and management. Hepatology 2012;56:1998-2000. [PMID: 23115011 DOI: 10.1002/hep.26080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
48 Harding SV, Fraser KG, Wykes LJ. Probiotics stimulate liver and plasma protein synthesis in piglets with dextran sulfate-induced colitis and macronutrient restriction. J Nutr 2008;138:2129-35. [PMID: 18936209 DOI: 10.3945/jn.108.090019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
49 Vaghef-mehrabany E, Homayouni-rad A, Alipour B, Sharif S, Vaghef-mehrabany L, Alipour-ajiry S. Effects of Probiotic Supplementation on Oxidative Stress Indices in Women with Rheumatoid Arthritis: A Randomized Double-Blind Clinical Trial. Journal of the American College of Nutrition 2015;35:291-9. [DOI: 10.1080/07315724.2014.959208] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
50 Anand G, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016;36:37-47. [PMID: 26870931 DOI: 10.1055/s-0035-1571276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
51 Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699-711. [PMID: 21292470 DOI: 10.1016/j.jnutbio.2010.10.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 11.3] [Reference Citation Analysis]
52 Uppal V, Mansoor S, Furuya KN. Pediatric Non-alcoholic Fatty Liver Disease. Curr Gastroenterol Rep 2016;18:24. [PMID: 27086005 DOI: 10.1007/s11894-016-0498-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
53 Stefan N, Kantartzis K, Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocrine Reviews 2008;29:939-60. [DOI: 10.1210/er.2008-0009] [Cited by in Crossref: 338] [Cited by in F6Publishing: 303] [Article Influence: 26.0] [Reference Citation Analysis]
54 Kobyliak N, Conte C, Cammarota G, Haley AP, Styriak I, Gaspar L, Fusek J, Rodrigo L, Kruzliak P. Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab (Lond). 2016;13:14. [PMID: 26900391 DOI: 10.1186/s12986-016-0067-0] [Cited by in Crossref: 140] [Cited by in F6Publishing: 104] [Article Influence: 28.0] [Reference Citation Analysis]
55 Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D, Bannazadeh Baghi H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis 2020;39:613-27. [PMID: 31828683 DOI: 10.1007/s10096-019-03746-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
56 Della Corte C, Liccardo D, Ferrari F, Alisi A, Nobili V. Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2014;15:2501-11. [DOI: 10.1517/14656566.2014.960389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
57 Jonkers D, Stockbrügger R. Review article: Probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther. 2007;26 Suppl 2:133-148. [PMID: 18081657 DOI: 10.1111/j.1365-2036.2007.03480.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
58 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
59 Pradere JP, Troeger JS, Dapito DH, Mencin AA, Schwabe RF. Toll-like receptor 4 and hepatic fibrogenesis. Semin Liver Dis. 2010;30:232-244. [PMID: 20665376 DOI: 10.1055/s-0030-1255353] [Cited by in Crossref: 91] [Cited by in F6Publishing: 85] [Article Influence: 8.3] [Reference Citation Analysis]
60 Meroni M, Longo M, Dongiovanni P. Alcohol or Gut Microbiota: Who Is the Guilty? Int J Mol Sci. 2019;20. [PMID: 31540133 DOI: 10.3390/ijms20184568] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 19.5] [Reference Citation Analysis]
61 Park SH. [Nonalcoholic steatohepatitis: pathogenesis and treatment]. Korean J Hepatol 2008;14:12-27. [PMID: 18367854 DOI: 10.3350/kjhep.2008.14.1.12] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
62 Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2008;28:503-22. [DOI: 10.1111/j.1365-2036.2008.03752.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 5.2] [Reference Citation Analysis]
63 Yu Q, Wu L, Ji J, Feng J, Dai W, Li J, Wu J, Guo C. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:271-88. [PMID: 33150145 DOI: 10.2147/JHC.S277870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
64 Abd El-Hack ME, Samak DH, Noreldin AE, El-Naggar K, Abdo M. Probiotics and plant-derived compounds as eco-friendly agents to inhibit microbial toxins in poultry feed: a comprehensive review. Environ Sci Pollut Res Int 2018;25:31971-86. [PMID: 30229484 DOI: 10.1007/s11356-018-3197-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
65 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases 2019;7:E27. [PMID: 30823570 DOI: 10.3390/diseases7010027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
66 McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012;112:401-409. [PMID: 22717200 DOI: 10.1016/j.jada.2011.10.007] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 10.1] [Reference Citation Analysis]
67 Darwish Murad S, Metselaar HJ. The invasion of fatty liver disease in liver transplantation. Transpl Int 2016;29:416-7. [PMID: 26497817 DOI: 10.1111/tri.12707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
68 Ceccarelli G, Statzu M, Santinelli L, Pinacchio C, Bitossi C, Cavallari EN, Vullo V, Scagnolari C, d'Ettorre G. Challenges in the management of HIV infection: update on the role of probiotic supplementation as a possible complementary therapeutic strategy for cART treated people living with HIV/AIDS. Expert Opin Biol Ther 2019;19:949-65. [PMID: 31260331 DOI: 10.1080/14712598.2019.1638907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
69 Chuang CH, Tsai CC, Lin ES, Huang CS, Lin YY, Lan CC, Huang CC. Heat-Killed Lactobacillus salivarius and Lactobacillus johnsonii Reduce Liver Injury Induced by Alcohol In Vitro and In Vivo. Molecules 2016;21:E1456. [PMID: 27809254 DOI: 10.3390/molecules21111456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
70 Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535-542. [PMID: 24401715 DOI: 10.3945/ajcn.113.068890] [Cited by in Crossref: 189] [Cited by in F6Publishing: 158] [Article Influence: 27.0] [Reference Citation Analysis]
71 Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487-500. [PMID: 24665862 DOI: 10.1586/17474124.2014.903798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
72 Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 2019;50:144-58. [PMID: 31149745 DOI: 10.1111/apt.15314] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
73 Sato Y. Encounter with childbirth in a sitting position. Josanpu Zasshi. 1985;39:802-803. [PMID: 3854811 DOI: 10.7812/tpp/12-144] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
74 Soriano G, Guarner C. Probiotics in cirrhosis: do we expect too much? Liver Int 2013;33:1451-3. [PMID: 24099262 DOI: 10.1111/liv.12288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
75 Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol. 2006;45:744-757. [PMID: 16979776 DOI: 10.1016/j.jhep.2006.08.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 4.8] [Reference Citation Analysis]
76 Floch MH, Walker WA, Sanders ME, Nieuwdorp M, Kim AS, Brenner DA, Qamar AA, Miloh TA, Guarino A, Guslandi M, Dieleman LA, Ringel Y, Quigley EM, Brandt LJ. Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus Opinion. J Clin Gastroenterol. 2015;49 Suppl 1:S69-S73. [PMID: 26447969 DOI: 10.1097/mcg.0000000000000420] [Cited by in Crossref: 74] [Cited by in F6Publishing: 20] [Article Influence: 14.8] [Reference Citation Analysis]
77 Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:315-22. [PMID: 16679470 DOI: 10.1136/pgmj.2005.042200] [Cited by in Crossref: 165] [Cited by in F6Publishing: 138] [Article Influence: 11.0] [Reference Citation Analysis]
78 Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut. 2009;58:704-720. [PMID: 19359436 DOI: 10.1136/gut.2008.156307] [Cited by in Crossref: 225] [Cited by in F6Publishing: 217] [Article Influence: 18.8] [Reference Citation Analysis]
79 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Reference Citation Analysis]
80 Houghton D, Stewart CJ, Day CP, Trenell M. Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci. 2016;17:447. [PMID: 27023533 DOI: 10.3390/ijms17040447] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
81 Fatima N, Akhtar T, Sheikh N. Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2017;2017:6238106. [PMID: 28573132 DOI: 10.1155/2017/6238106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
82 Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, Del Vecchio Blanco C, Loguercio C. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis. 2011;43:431-438. [PMID: 21163715 DOI: 10.1016/j.dld.2010.10.015] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 9.5] [Reference Citation Analysis]
83 Federico A, Trappoliere M, Loguercio C. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives. Dig Liver Dis. 2006;38:789-801. [PMID: 16750661 DOI: 10.1016/j.dld.2006.04.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
84 D'Argenio G, Cariello R, Tuccillo C, Mazzone G, Federico A, Funaro A, De Magistris L, Grossi E, Callegari ML, Chirico M. Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage? Liver Int. 2013;33:687-697. [PMID: 23448378 DOI: 10.1111/liv.12117] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
85 Spahis S, Delvin E, Borys JM, Levy E. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Antioxid Redox Signal. 2017;26:519-541. [PMID: 27452109 DOI: 10.1089/ars.2016.6776] [Cited by in Crossref: 173] [Cited by in F6Publishing: 150] [Article Influence: 34.6] [Reference Citation Analysis]
86 Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. J Nutr 2018;148:1276-84. [PMID: 29931231 DOI: 10.1093/jn/nxy088] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 20.0] [Reference Citation Analysis]
87 Wang Y, Li Y, Xie J, Zhang Y, Wang J, Sun X, Zhang H. Protective effects of probiotic Lactobacillus casei Zhang against endotoxin- and d-galactosamine-induced liver injury in rats via anti-oxidative and anti-inflammatory capacities. International Immunopharmacology 2013;15:30-7. [DOI: 10.1016/j.intimp.2012.10.026] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 8.5] [Reference Citation Analysis]
88 Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 2008;20:688-92. [PMID: 18679073 DOI: 10.1097/MEG.0b013e3282f5197e] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
89 Aron-wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clinical Microbiology and Infection 2013;19:338-48. [DOI: 10.1111/1469-0691.12140] [Cited by in Crossref: 141] [Cited by in F6Publishing: 128] [Article Influence: 17.6] [Reference Citation Analysis]
90 Kwon EK, Kang G, Kim W, Han MJ, Kim D. Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 simultaneously alleviate ethanol-induced gastritis and hepatic injury in mice. Journal of Functional Foods 2017;38:389-98. [DOI: 10.1016/j.jff.2017.09.036] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
91 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Reference Citation Analysis]
92 Jayakumar S, Carbonneau M, Hotte N, Befus AD, St Laurent C, Owen R, McCarthy M, Madsen K, Bailey RJ, Ma M. VSL#3® probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver Int. 2013;33:1470-1477. [PMID: 23968203 DOI: 10.1111/liv.12280] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
93 Qamar AA. Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis. J Clin Gastroenterol. 2015;49 Suppl 1:S28-S32. [PMID: 26447961 DOI: 10.1097/mcg.0000000000000347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
94 Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:16841-16857. [PMID: 25492998 DOI: 10.3748/wjg.v20.i45.16841] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
95 Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3:279-288. [PMID: 22572877 DOI: 10.4161/gmic.19625] [Cited by in Crossref: 431] [Cited by in F6Publishing: 362] [Article Influence: 47.9] [Reference Citation Analysis]
96 Chapman TM, Plosker GL, Figgitt DP. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs. 2006;66:1371-1387. [PMID: 16903771 DOI: 10.2165/00003495-200666100-00006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 4.3] [Reference Citation Analysis]
97 Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. Adv Exp Med Biol. 2018;1061:111-125. [PMID: 29956210 DOI: 10.1007/978-981-10-8684-7_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
98 Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48:670-678. [PMID: 18666225 DOI: 10.1002/hep.22399] [Cited by in Crossref: 136] [Cited by in F6Publishing: 132] [Article Influence: 10.5] [Reference Citation Analysis]
99 Lata J, Jurankova J, Kopacova M, Vitek P. Probiotics in hepatology. World J Gastroenterol. 2011;17:2890-2896. [PMID: 21734800 DOI: 10.3748/wjg.v17.i24.2890] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
100 Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. Int J Prev Med 2016;7:59. [PMID: 27076897 DOI: 10.4103/2008-7802.178533] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
101 Mehta SR. Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2010;1:101-115. [PMID: 23148155 DOI: 10.1177/2042018810379587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
102 Mizock BA. Probiotics. Disease-a-Month 2015;61:259-90. [DOI: 10.1016/j.disamonth.2015.03.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
103 Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis. 2013;45:543-551. [PMID: 23280158 DOI: 10.1016/j.dld.2012.11.010] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
104 Yu H. Bacteria-mediated disease therapy. Appl Microbiol Biotechnol 2011;92:1107-13. [DOI: 10.1007/s00253-011-3648-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
105 Wang Y, Xie J, Li Y, Dong S, Liu H, Chen J, Wang Y, Zhao S, Zhang Y, Zhang H. Probiotic Lactobacillus casei Zhang reduces pro-inflammatory cytokine production and hepatic inflammation in a rat model of acute liver failure. Eur J Nutr 2016;55:821-31. [PMID: 25893720 DOI: 10.1007/s00394-015-0904-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
106 Chen Y, Lin Y, Lin J, Yang N, Chen M. Sugary Kefir Strain Lactobacillus mali APS1 Ameliorated Hepatic Steatosis by Regulation of SIRT-1/Nrf-2 and Gut Microbiota in Rats. Mol Nutr Food Res 2018;62:1700903. [DOI: 10.1002/mnfr.201700903] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
107 Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9:321-328. [PMID: 21438811 DOI: 10.1586/erc.11.15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
108 Schaur RJ, Siems W, Bresgen N, Eckl PM. 4-Hydroxy-nonenal-A Bioactive Lipid Peroxidation Product. Biomolecules 2015;5:2247-337. [PMID: 26437435 DOI: 10.3390/biom5042247] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 14.8] [Reference Citation Analysis]
109 Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013;56:461-468. [PMID: 23287807 DOI: 10.1016/j.numecd.2012.02.007] [Cited by in Crossref: 229] [Cited by in F6Publishing: 218] [Article Influence: 28.6] [Reference Citation Analysis]
110 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 254] [Article Influence: 150.5] [Reference Citation Analysis]
111 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 69] [Article Influence: 12.7] [Reference Citation Analysis]
112 Malaguarnera G, Giordano M, Nunnari G, Bertino G, Malaguarnera M. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J Gastroenterol. 2014;20:16639-16648. [PMID: 25469033 DOI: 10.3748/wjg.v20.i44.16639] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 60] [Article Influence: 11.8] [Reference Citation Analysis]
113 O'Shea RS, Dasarathy S, McCullough AJ;  Practice Guideline Committee of the American Association for the Study of Liver Diseases;  Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010;51:307-328. [PMID: 20034030 DOI: 10.1002/hep.23258] [Cited by in Crossref: 750] [Cited by in F6Publishing: 624] [Article Influence: 68.2] [Reference Citation Analysis]
114 Raman M, Allard J. Non alcoholic fatty liver disease: a clinical approach and review. Can J Gastroenterol 2006;20:345-9. [PMID: 16691301 DOI: 10.1155/2006/918262] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
115 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
116 Rajani C, Jia W. Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders. Clin Sci (Lond) 2018;132:791-811. [PMID: 29661926 DOI: 10.1042/CS20171328] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
117 Zhu L, Baker RD, Baker SS. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res. 2015;77:245-251. [PMID: 25310763 DOI: 10.1038/pr.2014.157] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 10.4] [Reference Citation Analysis]
118 Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. Hepat Mon. 2013;13:e7521. [PMID: 23610585 DOI: 10.5812/hepatmon.7521] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
119 Abdelsayed GG. Diets in Encephalopathy. Clinics in Liver Disease 2015;19:497-505. [DOI: 10.1016/j.cld.2015.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
120 Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases. 2020;8:1361-1384. [PMID: 32368530 DOI: 10.12998/wjcc.v8.i8.1361] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
121 O'brien A, Williams R. Nutrition in End-Stage Liver Disease: Principles and Practice. Gastroenterology 2008;134:1729-40. [DOI: 10.1053/j.gastro.2008.02.001] [Cited by in Crossref: 98] [Cited by in F6Publishing: 80] [Article Influence: 7.5] [Reference Citation Analysis]
122 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014;20:12956-12980. [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 84] [Article Influence: 17.3] [Reference Citation Analysis]
123 AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 2015;16:393-405. [PMID: 25753407 DOI: 10.1111/obr.12271] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
124 Dornas W, Lagente V. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. Pharmacol Res. 2019;141:418-428. [PMID: 30658094 DOI: 10.1016/j.phrs.2019.01.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
125 Cerdó T, García-Santos JA, G Bermúdez M, Campoy C. The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity. Nutrients 2019;11:E635. [PMID: 30875987 DOI: 10.3390/nu11030635] [Cited by in Crossref: 91] [Cited by in F6Publishing: 59] [Article Influence: 45.5] [Reference Citation Analysis]
126 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
127 Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57:545-553. [PMID: 21901256 DOI: 10.1007/s10620-011-1887-4] [Cited by in Crossref: 238] [Cited by in F6Publishing: 207] [Article Influence: 23.8] [Reference Citation Analysis]
128 Rabot S, Rafter J, Rijkers GT, Watzl B, Antoine JM. Guidance for substantiating the evidence for beneficial effects of probiotics: impact of probiotics on digestive system metabolism. J Nutr. 2010;140:677S-689S. [PMID: 20107147 DOI: 10.3945/jn.109.113738] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
129 Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006;131:934-945. [PMID: 16952562 DOI: 10.1053/j.gastro.2006.05.054] [Cited by in Crossref: 241] [Cited by in F6Publishing: 216] [Article Influence: 16.1] [Reference Citation Analysis]
130 Shen TD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver: Microbiota and the Liver. Liver Transpl 2018;24:539-50. [DOI: 10.1002/lt.25008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
131 Wong VW, Wong GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Annals of Hepatology 2013;12:256-62. [DOI: 10.1016/s1665-2681(19)31364-x] [Cited by in Crossref: 158] [Article Influence: 19.8] [Reference Citation Analysis]
132 Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2021;41:87-102. [PMID: 33957682 DOI: 10.1055/s-0040-1719174] [Reference Citation Analysis]
133 Liu L, Li P, Liu Y, Zhang Y. Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Dig Dis Sci. 2019;64:3402-3412. [PMID: 31203554 DOI: 10.1007/s10620-019-05699-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
134 Xu RY, Wan YP, Fang QY, Lu W, Cai W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr. 2012;50:72-77. [PMID: 22247604 DOI: 10.3164/jcbn.11-38] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
135 Fung P, Pyrsopoulos N. Emerging concepts in alcoholic hepatitis. World J Hepatol 2017;9:567-85. [PMID: 28515843 DOI: 10.4254/wjh.v9.i12.567] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
136 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
137 Marchesini G, Moscatiello S, Agostini F, Villanova N, Festi D. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs 2011;16:121-36. [PMID: 21352073 DOI: 10.1517/14728214.2011.531700] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
138 Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011;13:692-702. [DOI: 10.1111/j.1463-1326.2011.01403.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
139 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
140 Vajro P, Lenta S, Pignata C, Salerno M, D’Aniello R, De Micco I, Paolella G, Parenti G. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr. 2012;38:55. [PMID: 23075296 DOI: 10.1186/1824-7288-38-55] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
141 Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int. 2018;12:24-33. [PMID: 28550391 DOI: 10.1007/s12072-017-9798-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 14.5] [Reference Citation Analysis]
142 Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev. 2010;11:430-445. [PMID: 19845871 DOI: 10.1111/j.1467-789x.2009.00657.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 52] [Article Influence: 9.8] [Reference Citation Analysis]
143 Vassallo G, Mirijello A, Ferrulli A, Antonelli M, Landolfi R, Gasbarrini A, Addolorato G. Review article: Alcohol and gut microbiota - the possible role of gut microbiota modulation in the treatment of alcoholic liver disease. Aliment Pharmacol Ther. 2015;41:917-927. [PMID: 25809237 DOI: 10.1111/apt.13164] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 10.2] [Reference Citation Analysis]
144 Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013;56:461-8. [PMID: 23287807 DOI: 10.1097/MPG.0b013e318284abb5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 52] [Article Influence: 14.6] [Reference Citation Analysis]
145 Jia W, Rajani C. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. Adv Exp Med Biol 2018;1061:95-110. [PMID: 29956209 DOI: 10.1007/978-981-10-8684-7_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
146 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 13.8] [Reference Citation Analysis]
147 Gu Z, Liu Y, Hu S, You Y, Wen J, Li W, Wang Y. Probiotics for Alleviating Alcoholic Liver Injury. Gastroenterol Res Pract 2019;2019:9097276. [PMID: 31263495 DOI: 10.1155/2019/9097276] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
148 Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol. 2012;2:132. [PMID: 23112961 DOI: 10.3389/fcimb.2012.00132.] [Reference Citation Analysis]
149 Cassard AM, Ciocan D. Microbiota, a key player in alcoholic liver disease. Clin Mol Hepatol 2018;24:100-7. [PMID: 29268595 DOI: 10.3350/cmh.2017.0067] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
150 Sherf-dagan S, Zelber-sagi S, Zilberman-schapira G, Webb M, Buch A, Keidar A, Raziel A, Sakran N, Goitein D, Goldenberg N, Mahdi JA, Pevsner-fischer M, Zmora N, Dori-bachash M, Segal E, Elinav E, Shibolet O. Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial. Int J Obes 2018;42:147-55. [DOI: 10.1038/ijo.2017.210] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
151 O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105:14-32; quiz 33. [PMID: 19904248 DOI: 10.1038/ajg.2009.593] [Cited by in Crossref: 154] [Cited by in F6Publishing: 129] [Article Influence: 12.8] [Reference Citation Analysis]
152 Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019;20:395. [PMID: 30658519 DOI: 10.3390/ijms20020395] [Cited by in Crossref: 82] [Cited by in F6Publishing: 63] [Article Influence: 41.0] [Reference Citation Analysis]
153 Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 2015;39:763-775. [PMID: 25872593 DOI: 10.1111/acer.12704] [Cited by in Crossref: 126] [Cited by in F6Publishing: 106] [Article Influence: 25.2] [Reference Citation Analysis]
154 Malyar RM, Naseri E, Li H, Ali I, Farid RA, Liu D, Maroof K, Nasim M, Banuree SAH, Huang K, Waldron KJ, Chen X. Hepatoprotective Effects of Selenium-Enriched Probiotics Supplementation on Heat-Stressed Wistar Rat Through Anti-Inflammatory and Antioxidant Effects. Biol Trace Elem Res 2021;199:3445-56. [PMID: 33161525 DOI: 10.1007/s12011-020-02475-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
155 Guerrero Hernández I, Torre Delgadillo A, Vargas Vorackova F, Uribe M. Intestinal flora, probiotics, and cirrhosis. Annals of Hepatology 2008;7:120-4. [DOI: 10.1016/s1665-2681(19)31866-6] [Cited by in Crossref: 10] [Article Influence: 0.8] [Reference Citation Analysis]
156 Solga SF, Buckley G, Clark JM, Horska A, Diehl AM. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol 2008;42:1117-9. [PMID: 18936646 DOI: 10.1097/MCG.0b013e31816d920c] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
157 Baratta F, Pastori D, Bartimoccia S, Cammisotto V, Cocomello N, Colantoni A, Nocella C, Carnevale R, Ferro D, Angelico F, Violi F, Del Ben M. Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E1732. [PMID: 32531941 DOI: 10.3390/nu12061732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
158 Abdel Monem SM. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. Euroasian J Hepatogastroenterol 2017;7:101-6. [PMID: 29201787 DOI: 10.5005/jp-journals-10018-1226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
159 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
160 Chong PL, Laight D, Aspinall RJ, Higginson A, Cummings MH. A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:144. [PMID: 33794784 DOI: 10.1186/s12876-021-01660-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Bengmark S. Bio-ecological control of chronic liver disease and encephalopathy. Metab Brain Dis. 2009;24:223-236. [PMID: 19104922 DOI: 10.1007/s11011-008-9128-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
162 Sánchez E, Nieto JC, Boullosa A, Vidal S, Sancho FJ, Rossi G, Sancho-Bru P, Oms R, Mirelis B, Juárez C. VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver Int. 2015;35:735-745. [PMID: 24750552 DOI: 10.1111/liv.12566] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
163 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 25.0] [Reference Citation Analysis]
164 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
165 Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41:1116-1131. [PMID: 25819304 DOI: 10.1111/apt.13172] [Cited by in Crossref: 83] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
166 Bajaj JS, Hylemon PB, Younossi Z. The Intestinal Microbiota and Liver Disease. Am J Gastroenterol Suppl 2012;1:9-14. [DOI: 10.1038/ajgsup.2012.3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
167 Dhanda AD, Lee RW, Collins PL, McCune CA. Molecular targets in the treatment of alcoholic hepatitis. World J Gastroenterol. 2012;18:5504-5513. [PMID: 23112542 DOI: 10.3748/wjg.v18.i39.5504] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
168 Chen HT, Huang HL, Li YQ, Xu HM, Zhou YJ. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. World J Gastroenterol 2020;26:1901-11. [PMID: 32390701 DOI: 10.3748/wjg.v26.i16.1901] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
169 Morgan MY, Blei A, Grüngreiff K, Jalan R, Kircheis G, Marchesini G, Riggio O, Weissenborn K. The treatment of hepatic encephalopathy. Metab Brain Dis 2007;22:389-405. [DOI: 10.1007/s11011-007-9060-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
170 Federico A, Dallio M, Godos J, Loguercio C, Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res. 2016;167:116-124. [PMID: 26318867 DOI: 10.1016/j.trsl.2015.08.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
171 Saberi B, Dadabhai AS, Jang YY, Gurakar A, Mezey E. Current Management of Alcoholic Hepatitis and Future Therapies. J Clin Transl Hepatol 2016;4:113-22. [PMID: 27350941 DOI: 10.14218/JCTH.2016.00006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
172 Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 2009;87:679-695. [PMID: 19352614 DOI: 10.1007/s00109-009-0464-1] [Cited by in Crossref: 188] [Cited by in F6Publishing: 161] [Article Influence: 15.7] [Reference Citation Analysis]
173 Corrado RL, Torres DM, Harrison SA. Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America 2014;98:55-72. [DOI: 10.1016/j.mcna.2013.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
174 Tandon P, Moncrief K, Madsen K, Arrieta MC, Owen RJ, Bain VG, Wong WW, Ma MM. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int. 2009;29:1110-1115. [PMID: 19490420 DOI: 10.1111/j.1478-3231.2009.02020.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
175 Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013;13:e7233. [PMID: 23885277 DOI: 10.5812/hepatmon.7233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
176 Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am 2010;39:57-68. [PMID: 20202579 DOI: 10.1016/j.gtc.2009.12.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
177 Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Annals of Hepatology 2009;8:S51-9. [DOI: 10.1016/s1665-2681(19)31827-7] [Cited by in Crossref: 26] [Article Influence: 2.2] [Reference Citation Analysis]
178 Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol. 2013;58:1020-1027. [PMID: 23183530 DOI: 10.1016/j.jhep.2012.11.023] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 8.3] [Reference Citation Analysis]
179 Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-alcoholic fatty liver disease: which and when. Annals of Hepatology 2013;12:357-63. [DOI: 10.1016/s1665-2681(19)30997-4] [Cited by in Crossref: 24] [Article Influence: 3.0] [Reference Citation Analysis]
180 Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007;11:1231-49. [PMID: 17845148 DOI: 10.1517/14728222.11.9.1231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
181 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
182 Higuera-de la Tijera F, Servín-Caamaño AI. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. World J Hepatol. 2015;7:1297-1301. [PMID: 26052375 DOI: 10.4254/wjh.v7.i10.1297] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
183 Lata J, Novotný I, Príbramská V, Juránková J, Fric P, Kroupa R, Stibůrek O. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007;19:1111-3. [PMID: 17998837 DOI: 10.1097/MEG.0b013e3282efa40e] [Cited by in Crossref: 78] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
184 Horvath A, Leber B, Schmerboeck B, Tawdrous M, Zettel G, Hartl A, Madl T, Stryeck S, Fuchs D, Lemesch S, Douschan P, Krones E, Spindelboeck W, Durchschein F, Rainer F, Zollner G, Stauber RE, Fickert P, Stiegler P, Stadlbauer V. Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Aliment Pharmacol Ther 2016;44:926-35. [PMID: 27593544 DOI: 10.1111/apt.13788] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
185 Yuan X, Pan Z, Jin C, Ni Y, Fu Z, Jin Y. Gut microbiota: An underestimated and unintended recipient for pesticide-induced toxicity. Chemosphere 2019;227:425-34. [PMID: 31003127 DOI: 10.1016/j.chemosphere.2019.04.088] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 28.0] [Reference Citation Analysis]
186 Kadayifci A, Merriman RB, Bass NM. Medical Treatment of Non-alcoholic Steatohepatitis. Clinics in Liver Disease 2007;11:119-40. [DOI: 10.1016/j.cld.2007.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
187 Kim WG, Kim HI, Kwon EK, Han MJ, Kim DH. Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 mitigate alcoholic steatosis in mice by inhibiting LPS-mediated NF-κB activation through restoration of the disturbed gut microbiota. Food Funct 2018;9:4255-65. [PMID: 30010169 DOI: 10.1039/c8fo00252e] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 7.3] [Reference Citation Analysis]
188 Mohammadmoradi S, Javidan A, Kordi J. Boom of probiotics: This time non-alcoholic fatty liver disease – A mini review. Journal of Functional Foods 2014;11:30-5. [DOI: 10.1016/j.jff.2014.08.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
189 D'Mello C, Ronaghan N, Zaheer R, Dicay M, Le T, MacNaughton WK, Surrette MG, Swain MG. Probiotics Improve Inflammation-Associated Sickness Behavior by Altering Communication between the Peripheral Immune System and the Brain. J Neurosci. 2015;35:10821-10830. [PMID: 26224864 DOI: 10.1523/jneurosci.0575-15.2015] [Cited by in Crossref: 100] [Cited by in F6Publishing: 39] [Article Influence: 16.7] [Reference Citation Analysis]
190 Lenoir-Wijnkoop I, Sanders ME, Cabana MD, Caglar E, Corthier G, Rayes N, Sherman PM, Timmerman HM, Vaneechoutte M, Van Loo J, Wolvers DA. Probiotic and prebiotic influence beyond the intestinal tract. Nutr Rev 2007;65:469-89. [PMID: 18038940 DOI: 10.1111/j.1753-4887.2007.tb00272.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 61] [Article Influence: 7.0] [Reference Citation Analysis]
191 Nardone G, Compare D, Liguori E, Di Mauro V, Rocco A, Barone M, Napoli A, Lapi D, Iovene MR, Colantuoni A. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. American Journal of Physiology-Gastrointestinal and Liver Physiology 2010;299:G669-76. [DOI: 10.1152/ajpgi.00188.2010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
192 Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011;52:740-3. [PMID: 21505361 DOI: 10.1097/MPG.0b013e31821f9b85] [Cited by in Crossref: 200] [Cited by in F6Publishing: 96] [Article Influence: 20.0] [Reference Citation Analysis]
193 Goodus MT, McTigue DM. Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? Exp Neurol 2020;325:113160. [PMID: 31863731 DOI: 10.1016/j.expneurol.2019.113160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
194 Nobili V, Svegliati-baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology 2013;58:1218-29. [DOI: 10.1016/j.jhep.2012.12.003] [Cited by in Crossref: 106] [Cited by in F6Publishing: 91] [Article Influence: 13.3] [Reference Citation Analysis]
195 McNear S, Harrison SA. Current status of therapy in nonalcoholic Fatty liver disease. Therap Adv Gastroenterol. 2009;2:29-43. [PMID: 21180532 DOI: 10.1177/1756283x08100327] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
196 Augustyn M, Grys I, Kukla M. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clin Exp Hepatol. 2019;5:1-10. [PMID: 30915401 DOI: 10.5114/ceh.2019.83151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
197 Valentini L, Pinto A, Bourdel-Marchasson I, Ostan R, Brigidi P, Turroni S, Hrelia S, Hrelia P, Bereswill S, Fischer A, Leoncini E, Malaguti M, Blanc-Bisson C, Durrieu J, Spazzafumo L, Buccolini F, Pryen F, Donini LM, Franceschi C, Lochs H. Impact of personalized diet and probiotic supplementation on inflammation, nutritional parameters and intestinal microbiota - The "RISTOMED project": Randomized controlled trial in healthy older people. Clin Nutr 2015;34:593-602. [PMID: 25453395 DOI: 10.1016/j.clnu.2014.09.023] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 10.1] [Reference Citation Analysis]
198 Vespasiani-Gentilucci U, Gallo P, Picardi A. The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. Arch Med Sci 2018;14:701-6. [PMID: 29765460 DOI: 10.5114/aoms.2016.58831] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
199 Reichold A, Brenner SA, Spruss A, Förster-Fromme K, Bergheim I, Bischoff SC. Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. J Nutr Biochem 2014;25:118-25. [PMID: 24445036 DOI: 10.1016/j.jnutbio.2013.09.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
200 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15518-15531. [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
201 Liu Y, Liu Q, Ye G, Khan A, Liu J, Gan F, Zhang X, Kumbhar S, Huang K. Protective effects of Selenium-enriched probiotics on carbon tetrachloride-induced liver fibrosis in rats. J Agric Food Chem 2015;63:242-9. [PMID: 25513970 DOI: 10.1021/jf5039184] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
202 Alisi A, Manco M, Vania A, Nobili V. Pediatric Nonalcoholic Fatty Liver Disease in 2009. The Journal of Pediatrics 2009;155:469-74. [DOI: 10.1016/j.jpeds.2009.06.014] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 7.2] [Reference Citation Analysis]
203 Zheng M, Xin Y, Li H, Cai X, Cui Y, Qiu L, Chen Y. Probiotics: A possible specific liver drug for non-alcoholic fatty liver disease. Bioscience Hypotheses 2009;2:54-5. [DOI: 10.1016/j.bihy.2008.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
205 Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep 2016;6:32002. [PMID: 27550547 DOI: 10.1038/srep32002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 22.8] [Reference Citation Analysis]
206 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Reference Citation Analysis]
207 Chávez-tapia NC, González-rodríguez L, Jeong M, López-ramírez Y, Barbero-becerra V, Juárez-hernández E, Romero-flores JL, Arrese M, Méndez-sánchez N, Uribe M. Current evidence on the use of probiotics in liver diseases. Journal of Functional Foods 2015;17:137-51. [DOI: 10.1016/j.jff.2015.05.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
208 Zhong W, Zhou Z. Alterations of the gut microbiome and metabolome in alcoholic liver disease. World J Gastrointest Pathophysiol 2014;5:514-22. [PMID: 25400995 DOI: 10.4291/wjgp.v5.i4.514] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
209 Heinritz SN, Mosenthin R, Weiss E. Use of pigs as a potential model for research into dietary modulation of the human gut microbiota. Nutr Res Rev 2013;26:191-209. [DOI: 10.1017/s0954422413000152] [Cited by in Crossref: 170] [Cited by in F6Publishing: 74] [Article Influence: 21.3] [Reference Citation Analysis]
210 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
211 He X, Ji G, Jia W, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci. 2016;17:300. [PMID: 26999104 DOI: 10.3390/ijms17030300] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
212 Bémeur C, Desjardins P, Butterworth RF. Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure. J Nutr Metab. 2010;2010:489823. [PMID: 21234351 DOI: 10.1155/2010/489823] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
213 Hörmannsperger G, Haller D. Molecular crosstalk of probiotic bacteria with the intestinal immune system: clinical relevance in the context of inflammatory bowel disease. Int J Med Microbiol. 2010;300:63-73. [PMID: 19828372 DOI: 10.1016/j.ijmm.2009.08.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
214 Miloh T. Probiotics in Pediatric Liver Disease. J Clin Gastroenterol 2015;49 Suppl 1:S33-6. [PMID: 26447962 DOI: 10.1097/MCG.0000000000000365] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
215 Poli G, Schaur R, Siems W, Leonarduzzi G. 4-Hydroxynonenal: A membrane lipid oxidation product of medicinal interest. Med Res Rev 2008;28:569-631. [DOI: 10.1002/med.20117] [Cited by in Crossref: 296] [Cited by in F6Publishing: 261] [Article Influence: 22.8] [Reference Citation Analysis]
216 Zhou Z, Zhong W. Targeting the gut barrier for the treatment of alcoholic liver disease. Liver Res 2017;1:197-207. [PMID: 30034913 DOI: 10.1016/j.livres.2017.12.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
217 Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266. [PMID: 19442917 DOI: 10.1016/j.cld.2009.02.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
218 Cariello R, Federico A, Sapone A, Tuccillo C, Scialdone VR, Tiso A, Miranda A, Portincasa P, Carbonara V, Palasciano G. Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. Dig Liver Dis. 2010;42:200-204. [PMID: 19502117 DOI: 10.1016/j.dld.2009.05.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
219 Lo RS, Austin AS, Freeman JG. Is there a role for probiotics in liver disease? ScientificWorldJournal 2014;2014:874768. [PMID: 25436233 DOI: 10.1155/2014/874768] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
220 Wang Y, Liu Y, Sidhu A, Ma Z, McClain C, Feng W. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol. 2012;303:G32-G41. [PMID: 22538402 DOI: 10.1080/07315724.2012.10720004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
221 Hillemacher T, Bachmann O, Kahl KG, Frieling H. Alcohol, microbiome, and their effect on psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2018;85:105-15. [PMID: 29705711 DOI: 10.1016/j.pnpbp.2018.04.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
222 Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. [PMID: 21180596 DOI: 10.1177/1756283X09359964] [Cited by in Crossref: 70] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
223 Leclercq S, Stärkel P, Delzenne NM, de Timary P. The gut microbiota: A new target in the management of alcohol dependence? Alcohol 2019;74:105-11. [PMID: 30031625 DOI: 10.1016/j.alcohol.2018.03.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
224 Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017;49:385-399. [PMID: 28600319 DOI: 10.1152/physiolgenomics.00012.2017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
225 Wall R, Ross RP, Shanahan F, O’mahony L, O’mahony C, Coakley M, Hart O, Lawlor P, Quigley EM, Kiely B, Fitzgerald GF, Stanton C. Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. The American Journal of Clinical Nutrition 2009;89:1393-401. [DOI: 10.3945/ajcn.2008.27023] [Cited by in Crossref: 121] [Cited by in F6Publishing: 106] [Article Influence: 10.1] [Reference Citation Analysis]
226 Aqaeinezhad Rudbane SM, Rahmdel S, Abdollahzadeh SM, Zare M, Bazrafshan A, Mazloomi SM. The efficacy of probiotic supplementation in rheumatoid arthritis: a meta-analysis of randomized, controlled trials. Inflammopharmacology 2018;26:67-76. [PMID: 29302905 DOI: 10.1007/s10787-017-0436-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
227 Brandi G, De Lorenzo S, Candela M, Pantaleo MA, Bellentani S, Tovoli F, Saccoccio G, Biasco G. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis 2017;38:231-40. [DOI: 10.1093/carcin/bgx007] [Cited by in Crossref: 104] [Cited by in F6Publishing: 44] [Article Influence: 26.0] [Reference Citation Analysis]
228 McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011;CD008716. [PMID: 22071855 DOI: 10.1002/14651858.cd008716.pub2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
229 Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009;51:212-223. [PMID: 19447517 DOI: 10.1016/j.jhep. 2009.03.008] [Reference Citation Analysis]
230 Scotti E, Boué S, Sasso GL, Zanetti F, Belcastro V, Poussin C, Sierro N, Battey J, Gimalac A, Ivanov NV, Hoeng J. Exploring the microbiome in health and disease: Implications for toxicology. Toxicology Research and Application 2017;1:239784731774188. [DOI: 10.1177/2397847317741884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
231 Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol 2015;21:1691-702. [PMID: 25684933 DOI: 10.3748/wjg.v21.i6.1691] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 70] [Article Influence: 13.3] [Reference Citation Analysis]
232 Yan AW, Schnabl B. Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol 2012;4:110-8. [PMID: 22567183 DOI: 10.4254/wjh.v4.i4.110] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 7.7] [Reference Citation Analysis]
233 Doğan B, Kemer Doğan ES, Özmen Ö, Fentoğlu Ö, Kırzıoğlu FY, Calapoğlu M. Synergistic Effect of Omega-3 and Probiotic Supplementation on Preventing Ligature-Induced Periodontitis. Probiotics Antimicrob Proteins 2021. [PMID: 34037942 DOI: 10.1007/s12602-021-09803-6] [Reference Citation Analysis]
234 Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:1756-67. [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
235 Patel F, Parwani K, Patel D, Mandal P. Metformin and Probiotics Interplay in Amelioration of Ethanol-Induced Oxidative Stress and Inflammatory Response in an In Vitro and In Vivo Model of Hepatic Injury. Mediators Inflamm 2021;2021:6636152. [PMID: 33953643 DOI: 10.1155/2021/6636152] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, Cave M. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008;42:675-682. [PMID: 19038698 DOI: 10.1016/j.alcohol.2008.08.006] [Cited by in Crossref: 252] [Cited by in F6Publishing: 224] [Article Influence: 21.0] [Reference Citation Analysis]
237 Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71-83. [PMID: 19914930 DOI: 10.1093/qjmed/hcp158] [Cited by in Crossref: 392] [Cited by in F6Publishing: 345] [Article Influence: 32.7] [Reference Citation Analysis]
238 Kosikowska U, Biernasiuk A, Korona-Głowniak I, Kiciak S, Tomasiewicz K, Malm A. The Association of Chronic Hepatitis C with Respiratory Microbiota Disturbance on the Basis of Decreased Haemophilus Spp. Colonization. Med Sci Monit 2016;22:625-32. [PMID: 26912163 DOI: 10.12659/msm.895544] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
239 Mastromarino P, Capobianco D, Miccheli A, Praticò G, Campagna G, Laforgia N, Capursi T, Baldassarre ME. Administration of a multistrain probiotic product (VSL#3) to women in the perinatal period differentially affects breast milk beneficial microbiota in relation to mode of delivery. Pharmacol Res 2015;95-96:63-70. [PMID: 25836922 DOI: 10.1016/j.phrs.2015.03.013] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
240 Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017;4. [PMID: 28767077 DOI: 10.3390/children4080066] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
241 Ekhlasi G, Zarrati M, Agah S, Hosseini AF, Hosseini S, Shidfar S, Soltani Aarbshahi SS, Razmpoosh E, Shidfar F. Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease. EXCLI J 2017;16:278-90. [PMID: 28507473 DOI: 10.17179/excli2016-846] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
242 Berardis S, Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr. 2014;173:131-139. [PMID: 24068459 DOI: 10.1007/s00431-013-2157-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 57] [Article Influence: 9.4] [Reference Citation Analysis]
243 Gupta H, Suk KT, Kim DJ. Gut Microbiota at the Intersection of Alcohol, Brain, and the Liver. J Clin Med 2021;10:541. [PMID: 33540624 DOI: 10.3390/jcm10030541] [Reference Citation Analysis]
244 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 6.7] [Reference Citation Analysis]
245 Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr. 2009;139:905-911. [PMID: 19321579 DOI: 10.3945/jn.108.101808] [Cited by in Crossref: 149] [Cited by in F6Publishing: 142] [Article Influence: 12.4] [Reference Citation Analysis]
246 Mehta AK, Lyon GM. Infectious diseases in end-stage liver disease patients. Crit Care Nurs Clin North Am. 2010;22:291-307. [PMID: 20691380 DOI: 10.1016/j.ccell.2010.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
247 Kang Y, Zhang X, Cai Y, Su J, Kong X. Gut microbiota and metabolic disease: from pathogenesis to new therapeutic strategies. Reviews in Medical Microbiology 2016;27:141-52. [DOI: 10.1097/mrm.0000000000000085] [Cited by in Crossref: 11] [Article Influence: 2.2] [Reference Citation Analysis]
248 Riordan SM, Skinner NA, Mciver CJ, Liu Q, Bengmark S, Bihari D, Visvanathan K. Synbiotic-associated improvement in liver function in cirrhotic patients: Relation to changes in circulating cytokine messenger RNA and protein levels. Microbial Ecology in Health and Disease 2009;19:7-16. [DOI: 10.1080/08910600601178709] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
249 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
250 Neish A. Probiotics of the Acidophilus Group: Lactobacillus acidophilus, delbrueckii subsp. bulgaricus and johnsonii. The Microbiota in Gastrointestinal Pathophysiology. Elsevier; 2017. pp. 71-8. [DOI: 10.1016/b978-0-12-804024-9.00006-9] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
251 Levitsky J. Probiotics: application of "healthy" bacteria to liver transplant recipients. Hepatology. 2006;44:507-510. [PMID: 16871567 DOI: 10.1002/hep.21256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
252 Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol. 2015;21:11597-11608. [PMID: 26556989 DOI: 10.3748/wjg.v21.i41.11597] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 47] [Article Influence: 10.2] [Reference Citation Analysis]
253 Iqbal S, Quigley EMM. Progress in Our Understanding of the Gut Microbiome: Implications for the Clinician. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-016-0524-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
254 Senol A, Isler M, Karahan AG, Kilic GB, Kuleasan H, Kaya S, Keskin M, Goren I, Saritas U, Aridogan BC. Preventive effect of probiotics and α-tocopherol on ethanol-induced gastric mucosal injury in rats. J Med Food. 2011;14:173-179. [PMID: 21244242 DOI: 10.1089/jmf.2010.0040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
255 Pratap Mouli V, Benjamin J, Bhushan Singh M, Mani K, Garg SK, Saraya A, Joshi YK. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: A non-inferiority randomized controlled trial. Hepatol Res. 2015;45:880-889. [PMID: 25266207 DOI: 10.1111/hepr.12429] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
256 Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 20.0] [Reference Citation Analysis]
257 Lu HF, Ren ZG, Li A, Zhang H, Xu SY, Jiang JW, Zhou L, Ling Q, Wang BH, Cui GY, Chen XH, Zheng SS, Li LJ. Fecal Microbiome Data Distinguish Liver Recipients With Normal and Abnormal Liver Function From Healthy Controls. Front Microbiol 2019;10:1518. [PMID: 31333622 DOI: 10.3389/fmicb.2019.01518] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
258 Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009;49:989-997. [PMID: 19115316 DOI: 10.1002/hep.22711] [Cited by in Crossref: 164] [Cited by in F6Publishing: 155] [Article Influence: 13.7] [Reference Citation Analysis]
259 Li F, Duan K, Wang C, McClain C, Feng W. Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms. Gastroenterol Res Pract 2016;2016:5491465. [PMID: 26839540 DOI: 10.1155/2016/5491465] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
260 Pleguezuelo M, Benitez JM, Jurado J, Montero JL, De la Mata M. Diagnosis and management of bacterial infections in decompensated cirrhosis. World J Hepatol. 2013;5:16-25. [PMID: 23383362 DOI: 10.4254/wjh.v5.i1.16] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
261 Machado MV, Cortez-pinto H. Gut microbiota and nonalcoholic fatty liver disease. Annals of Hepatology 2012;11:440-9. [DOI: 10.1016/s1665-2681(19)31457-7] [Cited by in Crossref: 99] [Article Influence: 11.0] [Reference Citation Analysis]
262 Ekhlasi G, Kolahdouz Mohammadi R, Agah S, Zarrati M, Hosseini AF, Arabshahi SS, Shidfar F. Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci 2016;21:106. [PMID: 28250783 DOI: 10.4103/1735-1995.193178] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
263 Marzuillo P, Del Giudice EM, Santoro N. Pediatric non-alcoholic fatty liver disease: New insights and future directions. World J Hepatol. 2014;6:217-225. [PMID: 24799990 DOI: 10.4254/wjh.v6.i4.217] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
264 Della Corte C, Liccardo D, Mosca A, Vania A, Nobili V. Non-alcoholic fatty liver disease. Paediatrics and Child Health 2013;23:529-34. [DOI: 10.1016/j.paed.2013.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
265 Jäger R, Purpura M, Stone JD, Turner SM, Anzalone AJ, Eimerbrink MJ, Pane M, Amoruso A, Rowlands DS, Oliver JM. Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 Supplementation Attenuates Performance and Range-of-Motion Decrements Following Muscle Damaging Exercise. Nutrients 2016;8:E642. [PMID: 27754427 DOI: 10.3390/nu8100642] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
266 Yin X, Peng J, Zhao L, Yu Y, Zhang X, Liu P, Feng Q, Hu Y, Pang X. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. Syst Appl Microbiol. 2013;36:188-196. [PMID: 23453736 DOI: 10.1016/j.syapm.2012.12.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
267 Yang L, Seki E. Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol 2012;3:138. [PMID: 22661952 DOI: 10.3389/fphys.2012.00138] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 8.9] [Reference Citation Analysis]
268 Gómez-hurtado I, Zapater P, Portune K, Juanola O, Fernández-iglesias A, González-navajas JM, Gracia-sancho J, Sanz Y, Francés R. Improved hemodynamic and liver function in portal hypertensive cirrhotic rats after administration of B. pseudocatenulatum CECT 7765. Eur J Nutr 2019;58:1647-58. [DOI: 10.1007/s00394-018-1709-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
269 Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;:CD005165. [PMID: 17253543 DOI: 10.1002/14651858.CD005165.pub2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
270 Lee JS, Paek NS, Kwon OS, Hahm KB. Anti-inflammatory actions of probiotics through activating suppressor of cytokine signaling (SOCS) expression and signaling in Helicobacter pylori infection: A novel mechanism. Journal of Gastroenterology and Hepatology 2010;25:194-202. [DOI: 10.1111/j.1440-1746.2009.06127.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
271 Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276-1285. [PMID: 24738701 DOI: 10.1111/apt.12758] [Cited by in Crossref: 232] [Cited by in F6Publishing: 189] [Article Influence: 33.1] [Reference Citation Analysis]
272 Tian X, Li R, Jiang Y, Zhao F, Yu Z, Wang Y, Dong Z, Liu P, Li X. Bifidobacterium breve ATCC15700 pretreatment prevents alcoholic liver disease through modulating gut microbiota in mice exposed to chronic alcohol intake. Journal of Functional Foods 2020;72:104045. [DOI: 10.1016/j.jff.2020.104045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
273 Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G. Microbial translocation in chronic liver diseases. Int J Microbiol 2012;2012:694629. [PMID: 22848224 DOI: 10.1155/2012/694629] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
274 Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19:6911-6918. [PMID: 24187469 DOI: 10.3748/wjg.v19.i40.6911] [Cited by in CrossRef: 191] [Cited by in F6Publishing: 163] [Article Influence: 27.3] [Reference Citation Analysis]
275 Rayes N, Pilarski T, Stockmann M, Bengmark S, Neuhaus P, Seehofer D. Effect of pre- and probiotics on liver regeneration after resection: a randomised, double-blind pilot study. Benef Microbes. 2012;3:237-244. [PMID: 22968413 DOI: 10.3920/bm2012.0006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
276 Vitetta L, Manuel R, Zhou JY, Linnane AW, Hall S, Coulson S. The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures. Pharmaceuticals (Basel) 2014;7:954-89. [PMID: 25244509 DOI: 10.3390/ph7090954] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
277 Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol 2012;2:132. [PMID: 23112961 DOI: 10.3389/fcimb.2012.00132] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]